Quantitative analysis for Black Diamond Therapeutics, Inc. (BDTX) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (39.0) (grade D). 29 signals analyzed (24 differentiated alt-data).
BDTX stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $2.74 | $2.55 | $2.57 |
| 2026-05-11 | $3.18 | $2.92 | $2.94 |
| 2026-05-21 | $3.90 | $3.47 | $3.55 |
| 2026-06-03 | $2.18 | $2.07 | $2.10 |
| 2026-06-15 | $1.88 | $1.72 | $1.72 |
| 2026-06-26 | $1.77 | $1.68 | $1.71 |
| 2026-07-09 | $1.95 | $1.87 | $1.88 |
| 2026-07-21 | $1.88 | $1.78 | $1.87 |
| 2026-07-31 | $1.71 | $1.62 | $1.69 |
| 2026-08-12 | $2.14 | $2.02 | $2.10 |
| 2026-08-24 | $2.22 | $2.13 | $2.15 |
| 2026-09-03 | $2.17 | $2.06 | $2.10 |
How Black Diamond Therapeutics, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| TENX | Tenax Therapeutics, Inc. | $206M | — |
| INFU | InfuSystem Holdings, Inc. | $205M | — |
| CNTX | Context Therapeutics Inc. | $205M | — |
| WHWK | Whitehawk Therapeutics Inc | $209M | — |
View all Health Care stocks by valuation and signals →
Black Diamond Therapeutics, Inc. (BDTX) scores Sell (39.0), and the composite conceals a 79-point disagreement between its dimensions. It is strongest on ML forecast at 82, and weakest on technicals at 15 and analyst consensus at 3. A stock can carry ML forecast that high while analyst consensus sits at 3; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| ML forecast | 82 |
| competitive moat | 27 |
| technicals | 15 |
| analyst consensus | 3 |
StoQuant analyzes 29 signals (24 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Black Diamond Therapeutics, Inc. (BDTX): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/BDTX"><img src="https://stoquant.com/badge/BDTX.svg" alt="Black Diamond Therapeutics, Inc. (BDTX) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.